Dirty Drugs -- Electrophysiologic Complications of Cancer Treatments-Dirty Drugs -- Electrophysiologic Complications of Cancer Treatments

Video Transcription

Video Summary

The "Dirty Drugs Electrophysiologic Complications of Cancer Treatments" session, moderated by Jim Tisdale from Purdue University and Estelle Torbay from Brown University, explored the electrophysiological issues arising from cancer treatments. Dr. Michael Fradley discussed the prevalence and management of atrial fibrillation in cancer patients, noting that cancer treatments such as BTK inhibitors and immunotherapies often lead to arrhythmias. He highlighted the need for improved care management strategies, emphasizing that current AFib management recommendations should more broadly include anticoagulants like DOACs despite common treatment pitfalls such as drug interactions and bleeding risks.<br /><br />Dr. Zainal Abidin Assad focused on the issue of ventricular arrhythmias and QT prolongation due to cancer therapies. He emphasized the need to monitor QT intervals, particularly when certain medications are involved, such as arsenic compounds and tyrosine kinase inhibitors. Dr. Iona Cosmo Dow addressed bradycardia and conduction system disease in cancer patients, pointing out cancer therapies' risks related to these cardiac complications. Lastly, Dr. Kaveh Karimzad discussed autonomic dysfunction, particularly orthostatic hypotension, in cancer patients, highlighting treatment challenges, especially for those who have undergone head and neck radiation. The session underscored the importance of understanding these complications to ensure better management and outcomes in cancer patients receiving cardiotoxic therapies.

Keywords

electrophysiologic complications

cancer treatments

atrial fibrillation

arrhythmias

QT prolongation

ventricular arrhythmias

bradycardia

autonomic dysfunction

cardiotoxic therapies

management strategies